Servier

Founded 70 years ago to serve health, Servier is a global pharmaceutical group overseen by a non-profit Foundation, aiming to create meaningful social impact for patients and a sustainable world. This unique governance model ensures its independence, enabling it to fully pursue its mission of advancing therapeutics to meet patient needs with a long-term perspective. Employees are entirely dedicated to this shared mission, which inspires them daily. As a global leader in cardiometabolism and venous diseases, Servier has significantly expanded into oncology, now a key pillar of its strategic growth. The Group allocates nearly 70% of its R&D budget to this area, aiming to become a focused and innovative player in treating rare cancers. Neurology is slated as a future growth driver, with Servier concentrating on a select set of diseases where precise patient profiling allows for targeted therapies via precision medicine. To ensure broad access to affordable, quality care, the Group also provides a range of generic drugs covering most conditions, relying on established brands in France, Eastern Europe, and Brazil. Across these fields, patient needs are addressed at each phase of the medicine’s lifecycle. Based in France, Servier benefits from dedicated teams and an extensive global presence, with medications available in nearly 140 countries. In 2023/2024, the Group reported sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Currently, the Group employs more than 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com